Skip to content
Tenfell
Awarded contract
Published 29 Jul 2025

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS England · London

Key facts

Awarded
30 Jun 2025
Procedure
Open procedure (framework)
Buyer type
Central government

Awarded to 21 suppliers

SupplierValue
Biogen—
Amgen Ltd—
Sobi (Swedish Orphan Biovitrum Ltd)—
Zentiva Pharma UK Ltd—
FRESENIUS KABI LIMITED—
Sandoz Ltd—
Thornton & Ross Ltd—
Roche Products Ltd—
Accord-UK Ltd—
GlaxoSmithKline—
Samsung Bioepis Ltd—
Pfizer Ltd—
Janssen-Cilag Ltd—
Celltrion Healthcare United Kingdom Limited—
Abbvie Ltd—
Takeda UK Limited—
Organon Pharmaceuticals UK Ltd—
Alexion Pharmaceuticals—
Orifarm UK—
CuraTeQ Biologics s.r.o.—
Dr Reddy's Laboratories (UK) Ltd—

Description

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Find a Tender (Open Government Licence v3.0). Always read the original notice before responding.